Cargando…

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy

SIMPLE SUMMARY: Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) mutations usually benefit from targeted therapy treatment. Nonetheless, primary or acquired resistance mechanisms lead to treatment dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canale, Matteo, Andrikou, Kalliopi, Priano, Ilaria, Cravero, Paola, Pasini, Luigi, Urbini, Milena, Delmonte, Angelo, Crinò, Lucio, Bronte, Giuseppe, Ulivi, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909869/ https://www.ncbi.nlm.nih.gov/pubmed/35267450 http://dx.doi.org/10.3390/cancers14051143

Ejemplares similares

Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients
por: Ulivi, Paola, et al.
Publicado: (2022)

The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer
por: Verlicchi, Alberto, et al.
Publicado: (2023)

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
por: Ulivi, Paola, et al.
Publicado: (2021)

High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis
por: Bronte, Giuseppe, et al.
Publicado: (2022)

Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer
por: Andrikou, Kalliopi, et al.
Publicado: (2023)

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
por: Canale, Matteo, et al.
Publicado: (2020)

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
por: Canale, Matteo, et al.
Publicado: (2022)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma
por: Gianni, Caterina, et al.
Publicado: (2021)

Unveiling mutational dynamics in non‐small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA
por: Pasini, Luigi, et al.
Publicado: (2021)

Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
por: Danesi, Valentina, et al.
Publicado: (2022)

Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR
por: Siggillino, Annamaria, et al.
Publicado: (2020)

Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer
por: De Matteis, Serena, et al.
Publicado: (2019)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study
por: Syahruddin, Elisna, et al.
Publicado: (2022)

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

Comparative Analysis of Free-Circulating and Vesicle-Associated Plasma microRNAs of Healthy Controls and Early-Stage Lung Cancer Patients
por: Pasini, Luigi, et al.
Publicado: (2022)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
por: Monti, Paola, et al.
Publicado: (2020)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Concordance of Abundance for Mutational EGFR and Co-Mutational TP53 with Efficacy of EGFR-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer
por: Wang, Youping, et al.
Publicado: (2023)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
por: Roeper, Julia, et al.
Publicado: (2020)

Mutational processes shape the landscape of TP53 mutations in human cancer
por: Giacomelli, Andrew O., et al.
Publicado: (2018)

Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
por: Liu, Surui, et al.
Publicado: (2022)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
por: Brachova, Pavla, et al.
Publicado: (2013)

TP53 mutations on circulating cell-free DNA
por: Pantel, Klaus
Publicado: (2016)

Germline mutation in the TP53 gene in uveal melanoma
por: Hajkova, Nikola, et al.
Publicado: (2018)

Immunohistochemical correlates of TP53 somatic mutations in cancer
por: Murnyák, Balázs, et al.
Publicado: (2016)

Mesonephric Adenocarcinoma of the Vagina Harboring TP53 Mutation
por: Lee, Hyunjee, et al.
Publicado: (2022)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

TP53 mutations in Romanian patients with colorectal cancer
por: Manirakiza, Felix, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kf6pj17qasl0uubgngnk7ccu1t